United States Food and Drug Administration (US FDA) had conducted an inspection at API manufacturing facility of the Company at Plot No. E-22, MIDC, Tarapur, Maharashtra. Now the Company is in receipt of the Establishment Inspection Report (EIR). EIR is a report which includes details of audit done.
FDA has determined that the inspection classification of this facility is "voluntary action indicated" (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).
There are no financial or material impacts as on date. Company is in receipt of the Establishment Inspection Report (EIR) from US FDA concluding the inspection as closed under 21 CFR 20.64(d)(3). Due to this Company can export the products such as Ciprofloxacin HCl API, Zolpidem Tartrate API, Raloxifene HCl API, Celecoxib API and Niacin API in US Market.
Shares of Aarti Drugs Limited was last trading in BSE at Rs. 471.10 as compared to the previous close of Rs. 423.95. The total number of shares traded during the day was 65026 in over 3584 trades.
The stock hit an intraday high of Rs. 495.75 and intraday low of 420.15. The net turnover during the day was Rs. 30301152.00. |
